目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T26375 | Dopamine Receptor 5-HT Receptor | ||
(S)-Amisulpride ((S) Amisulpride) 是一种有效的多巴胺D2/D3受体拮抗剂,具有抗精神和抗抑郁作用。它是5-HT7受体的拮抗剂,KI 值为 900 nM。 | |||
T0185 | Dopamine Receptor 5-HT Receptor Serotonin Transporter Adrenergic Receptor AChR Norepinephrine Histamine Receptor | ||
Escitalopram (Seroplex) 是一种外消旋 Citalopram 的 S-对映体,是一种选择性 5-羟色胺再摄取抑制剂,Ki=0.89 nM,比 R(-)-enantiomer 结合亲和力高 30 倍。它对多巴胺转运体和去甲肾上腺素转运体均有选择性,是一种研究抑郁症的抗抑郁药。 | |||
T2141 | AChR | ||
Mecamylamine hydrochloride (Mevasin) 是一种易穿过血脑屏障的烟碱拮抗剂,用作高血压的神经节阻滞剂,具有抗神经疾病作用。 | |||
T6241 | Dopamine Receptor 5-HT Receptor Adrenergic Receptor | ||
Quetiapine hemifumarate (ICI-204636) 是5-HT 受体激动剂和多巴胺受体拮抗剂,对人5-HT1A 和人D2的pEC50值分别为 4.77 和 6.33,具有抗抑郁和抗焦虑作用。 | |||
T0472 | 5-HT Receptor Serotonin Transporter | ||
Venlafaxine hydrochloride (Wy 45030 hydrochloride) 是一种口服有效的 5-羟色胺 (5-HT)/去甲肾上腺素 (NE) 重摄取的双重抑制剂,具有抗抑郁活性。 | |||
T6714 | Mitophagy FAAH Autophagy | ||
URB-597 (FAAH Inhibitor II) 是一种可口服的选择性FAAH 抑制剂。 它抑制大鼠脑膜、体外大鼠神经元和人肝微粒体中的 FAAH 活性,IC50分别为 5、0.5和 3 nM。它具有抗抑郁样作用,可研究缓解疼痛。 | |||
T6493 | Others 5-HT Receptor Serotonin Transporter | ||
Escitalopram Oxalate ((S)-(+)Citalopram oxalate) 是一种外消旋 Citalopram 的 S-对映体,是一种选择性 5-羟色胺再摄取抑制剂,Ki=0.89 nM,比 R(-)-enantiomer 结合亲和力高 30 倍。它对多巴胺转运体和去甲肾上腺素转运体均有选择性,是一种研究抑郁症的抗抑郁药。 | |||
T1909 | NMDAR iGluR | ||
L-701324 是一种 NMDA 受体,对甘氨酸位点具有高亲和力和选择性,用作口服活性和长效抗惊厥药。 | |||
T0255 | Dopamine Receptor 5-HT Receptor Serotonin Transporter Norepinephrine GST | ||
Clomipramine hydrochloride (Anafranil) 是一种5-羟色胺转运体(Ki:0.14 nM)、去甲肾上腺素转运体(Ki:54 nM)和多巴胺转运体(Ki:3 nM)阻断剂。 | |||
T3275 | 5-HT Receptor Adrenergic Receptor | ||
Nefazodone hydrochloride (Serzone) 是一种强效和选择性的5HT2A 拮抗剂,Ki 为5.8 nM,对 5-HT 和去甲肾上腺素摄取具有中度抑制作用,IC50分别为 290 和 300 nM。它是一种苯哌嗪类抗抑郁药,具有微弱的 α-肾上腺素阻断活性,用于治疗抑郁症、攻击性行为和恐慌症。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-00859 | HTR1B Protein, Human, Recombinant (His) | Human | in vitro E. coli expression system | ||
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries.
|
|||||
TMPH-00861 | HTR1D Protein, Human, Recombinant (His & KSI) | Human | E. coli | ||
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction.
|
|||||
TMPH-00860 | HTR1D Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction.
|